AnaptysBio (ANAB) financial statements
AnaptysBio reported revenue of $235M in fiscal 2025, up 34.1% a year over 9 years.
Net income was -$13M and the operating margin 96.7%, against -18.1% in 2016.
Free cash flow was $20M, and the company returned $69M in net buybacks.
The diluted share count rose 1046% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from AnaptysBio's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17M | $10M | $5M | $8M | $75M | $63M | $10M | $17M | $91M | $235M |
| Research and development | $15M | $29M | $56M | $99M | $80M | $98M | $89M | $132M | $164M | $136M |
| Selling, general and admin | $4M | $9M | $16M | $16M | $19M | $21M | $37M | $42M | $14M | $11M |
| Operating income | -$3M | -$29M | -$67M | -$107M | -$24M | -$57M | -$115M | -$164M | $66M | $227M |
| Interest expense | $458,000 | $2M | $2M | $1M | $0 | $0 | — | — | — | — |
| Pre-tax income | -$4M | -$30M | -$62M | -$97M | -$20M | -$58M | -$129M | -$164M | $31M | $162M |
| Income tax | $0 | $0 | -$192,000 | -$152,000 | $0 | $0 | $24,000 | -$4,000 | $158,000 | $772,000 |
| Net income | -$4M | -$30M | -$62M | -$97M | -$20M | -$58M | -$129M | -$164M | -$145M | -$13M |
| EPS (diluted) | -$1.62 | -$1.52 | -$2.50 | -$3.60 | -$0.73 | -$2.11 | -$4.57 | -$6.08 | -$4.92 | -$0.44 |
| Diluted shares | 3M | 20M | 25M | 27M | 27M | 27M | 28M | 27M | 30M | 30M |
| Operating margin | -18.1% | -287.8% | -1334.4% | -1342.9% | -31.8% | -89.9% | -1119.4% | -958.3% | 72.5% | 96.7% |
| Net margin | -25.5% | -300.7% | -1233.1% | -1216.7% | -26.6% | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
Balance sheet
Fiscal years, from AnaptysBio's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $51M | $248M | $427M | $374M | $394M | $548M | $441M | $391M | $285M | $212M |
| Receivables | $1M | $0 | $0 | $0 | $0 | $876,000 | $1M | $7M | $41M | $34M |
| Total current assets | $58M | $253M | $434M | $378M | $397M | $554M | $447M | $407M | $432M | $350M |
| Property, plant and equipment | $471,000 | $665,000 | $1M | $2M | $2M | $2M | $2M | $2M | $131,000 | $111,000 |
| Total assets | $62M | $329M | $509M | $435M | $417M | $643M | $610M | $452M | $484M | $364M |
| Total current liabilities | $6M | $14M | $22M | $30M | $20M | $16M | $26M | $37M | $45M | $39M |
| Total liabilities | $100M | $22M | $23M | $30M | $20M | $287M | $348M | $364M | $413M | $327M |
| Shareholders' equity | -$38M | $308M | $486M | $405M | $397M | $356M | $262M | $88M | $71M | $37M |
| Net debt | -$51M | -$81M | -$114M | -$171M | -$250M | -$496M | -$71M | -$36M | -$23M | -$138M |
Cash flow
Fiscal years, from AnaptysBio's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9M | -$19M | -$49M | -$70M | -$14M | -$46M | -$74M | -$121M | -$135M | $20M |
| Capital spending | $50,000 | $290,000 | $1M | $805,000 | $569,000 | $1M | $358,000 | $807,000 | $358,000 | $87,000 |
| Free cash flow | -$9M | -$20M | -$50M | -$70M | -$15M | -$47M | -$74M | -$122M | -$136M | $20M |
| Stock-based compensation | $1M | $4M | — | — | — | $15M | $27M | $33M | $7M | $4M |
| Share buybacks (net) | -$1,000 | $0 | $0 | — | — | $0 | $0 | -$50M | -$456,000 | -$69M |
| Free cash flow margin | -54.4% | -197.3% | -991.4% | -879.0% | -19.6% | -74.8% | -718.9% | -708.8% | -148.7% | 8.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANAB.
Open ANAB in InvestinglyQuestions
What was AnaptysBio's revenue in 2025?
$235M in fiscal 2025, from its 10-K filing.
How much free cash flow does AnaptysBio generate?
$20M in fiscal 2025 (operating cash flow minus capital spending).
From AnaptysBio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.